Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fructooligosaccharide (FOS) is a group of short-chain oligosaccharide carbohydrates composed of fructose units (and sometimes terminal glucose) linked by β(2→1) glycosidic bonds[2][3][4][1]. FOS resists digestion in the human upper gastrointestinal tract, reaching the colon where it acts as a prebiotic—selectively stimulating the growth of beneficial bacteria such as bifidobacteria and lactobacilli, and supporting the production of health-promoting short-chain fatty acids[1][4][3]. Naturally occurring in many plants, commercial FOS is typically synthesized from sucrose or extracted from inulin-rich sources like chicory root[2][1]. FOS is widely used as a functional food ingredient and sweetener with about 30–50% the sweetness of sucrose[2], but it is not a biological receptor, drug target, or molecular signaling entity. Instead, it plays a dietary role in microbiome modulation and digestive health, but should not be classified as a therapeutic target such as a receptor, enzyme, transporter, or similar molecule[2][3][4].
Not a direct drug target. Mechanism relates to being fermented by gut bacteria, thereby supporting beneficial microbiota and the production of SCFAs
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fructooligosaccharide (FOS).